Albany Molecular Research has the Highest Debt to EBITDA Ratio in the Life Sciences Tools & Services Industry (AMRI, TMO, AFFX, QGEN, CRL)
Below are the three companies in the Life Sciences Tools & Services industry with the highest debt to EBITDA ratios. This ratio indicates how many years of EBITDA would be necessary in order to pay back all the debt (assuming Debt and EBITDA are constant). Typically, this ratio is considered to be alarming when it is greater than 3.0 but this can vary and should be looked at within the context of the industry.
Albany Molecular Research ranks highest with a a debt to EBITDA ratio of 10.5. Thermo Fisher Scientific is next with a a debt to EBITDA ratio of 3.3. Affymetrix ranks third highest with a a debt to EBITDA ratio of 3.0.
QIAGEN follows with a a debt to EBITDA ratio of 3.0, and Charles River Laboratories rounds out the top five with a a debt to EBITDA ratio of 2.9.
SmarTrend recommended that subscribers consider buying shares of Charles River Laboratories on July 8th, 2016 as our technology indicated a new Uptrend was in progress when shares hit $85.11. Since that recommendation, shares of Charles River Laboratories have risen 3.9%. We continue to monitor Charles River Laboratories for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: highest debt to ebitda ratio albany molecular research thermo fisher scientific Affymetrix qiagen charles river laboratories